Systemic treatment for prostate cancer.
Prostate cancer is a leading cause of cancer mortality in adult men. The majority of patients have subclinical systemic disease at diagnosis and will eventually require systemic therapy for palliation of symptoms. Recent development of new hormonal treatment options (e.g., gonadotropin-releasing hormone analogues and estramustine) has yet to demonstrate potential for improving the therapeutic index or for lengthening survival over results achieved with traditional modalities (i.e., supplemental estrogens or castration). Chemotherapeutic agents have demonstrated palliative efficacy and are being tested in multidrug regimens and in combination with hormones. At the present time, the optimal use of cytotoxic drugs remains undefined, since recently published studies have shown neither that combination chemotherapy is superior to single agents nor that chemo-hormonal therapy produces more favorable results than hormonal treatment alone.
Lyss
A P
AP
Washington University School of Medicine, Division of Hematology/Oncology, St. Louis, Missouri.
D000135:Acid Phosphatase / Q000097:blood; D000728:Androgens / Q000097:blood; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary; D002455:Cell Division; D004054:Diethylstilbestrol / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology / Q000628:therapy*; D013739:Testosterone / Q000097:blood
D000728:Androgens; D000970:Antineoplastic Agents; D013739:Testosterone; D004054:Diethylstilbestrol; D000135:Acid Phosphatase